<?xml version="1.0" encoding="utf-8"?> <feed xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/" xmlns="http://www.w3.org/2005/Atom"> <title type="text">Knight Therapeutics</title> <subtitle type="text">Contains the last 20 releases</subtitle> <id>uuid:16b24de2-b5eb-4cd8-8a48-fd274f8f9502;id=13436</id> <rights type="text">Copyright 2024, Knight Therapeutics</rights> <updated>2024-11-14T21:30:00Z</updated> <author> <name>newsdesk@globenewswire.com (NewsDesk)</name> <uri>http://www.globenewswire.com/LegacyRss?Length=4</uri> <email>newsdesk@globenewswire.com</email> </author> <link rel="alternate" href="https://www.globenewswire.com/atomfeed/organization/89g8OyasD9WOPwmxmGU0Kg==" /> <link rel="self" href="https://www.globenewswire.com/atomfeed/organization/89g8OyasD9WOPwmxmGU0Kg==" /> <entry> <id>https://www.globenewswire.com/news-release/2024/11/14/2981656/0/en/Knight-Therapeutics-Announces-Health-Canada-Approval-for-JORNAY-PM-to-Treat-Attention-Deficit-Hyperactivity-Disorder-ADHD.html</id> <title type="text">Knight Therapeutics Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder (ADHD)</title> <published>2024-11-14T21:30:00Z</published> <updated>2024-11-22T15:07:27Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/11/14/2981656/0/en/Knight-Therapeutics-Announces-Health-Canada-Approval-for-JORNAY-PM-to-Treat-Attention-Deficit-Hyperactivity-Disorder-ADHD.html" /> <category term="TSX:GUD" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA4990531069" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">MONTREAL, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved <strong>JORNAY PM</strong>™, an extended-release formulation of methylphenidate, a stimulant medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in children.</p>]]></content> <dc:identifier>2981656</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Knight Therapeutics</dc:contributor> <dc:modified>Thu, 14 Nov 2024 21:30 GMT</dc:modified> <dc:subject>Management statements</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/11/14/2981656/0/fr/Th%C3%A9rapeutique-Knight-annonce-l-approbation-par-Sant%C3%A9-Canada-de-JORNAY-PM-MC-pour-le-traitement-du-trouble-de-d%C3%A9ficit-d-attention-avec-hyperactivit%C3%A9-TDAH.html</id> <title type="text">Thérapeutique Knight annonce l’approbation par Santé Canada de JORNAY PM(MC) pour le traitement du trouble de déficit d’attention avec hyperactivité (TDAH)</title> <published>2024-11-14T21:30:00Z</published> <updated>2024-11-22T15:07:27Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/11/14/2981656/0/fr/Th%C3%A9rapeutique-Knight-annonce-l-approbation-par-Sant%C3%A9-Canada-de-JORNAY-PM-MC-pour-le-traitement-du-trouble-de-d%C3%A9ficit-d-attention-avec-hyperactivit%C3%A9-TDAH.html" /> <category term="TSX:GUD" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA4990531069" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">MONTRÉAL, 14 nov. 2024 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight »), société pharmaceutique spécialisée panaméricaine (hors États-Unis), a annoncé aujourd’hui l’approbation par Santé Canada de <strong>JORNAY PM</strong><sup><strong>MC</strong></sup>, une formulation à libération prolongée de méthylphénidate, médicament stimulant pour le traitement du trouble du déficit de l’attention avec hyperactivité (TDAH) des enfants. </p>]]></content> <dc:identifier>2981656</dc:identifier> <dc:language>fr</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Thérapeutique Knight inc.</dc:contributor> <dc:modified>Thu, 14 Nov 2024 21:30 GMT</dc:modified> <dc:subject>Management statements</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/11/07/2976557/0/en/Knight-Therapeutics-Reports-Third-Quarter-2024.html</id> <title type="text">Knight Therapeutics Reports Third Quarter 2024</title> <published>2024-11-07T12:30:00Z</published> <updated>2024-11-22T15:07:27Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/11/07/2976557/0/en/Knight-Therapeutics-Reports-Third-Quarter-2024.html" /> <category term="TSX:GUD" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA4990531069" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">MONTREAL, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2024. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified.</p>]]></content> <dc:identifier>2976557</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Knight Therapeutics</dc:contributor> <dc:modified>Thu, 07 Nov 2024 12:30 GMT</dc:modified> <dc:subject>Calendar of Events</dc:subject> <dc:subject>Earnings Releases and Operating Results</dc:subject> <dc:subject>Conference Calls/ Webcasts</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/11/07/2976557/0/fr/Th%C3%A9rapeutique-Knight-d%C3%A9clare-ses-r%C3%A9sultats-du-troisi%C3%A8me-trimestre-de-2024.html</id> <title type="text">Thérapeutique Knight déclare ses résultats du troisième trimestre de 2024</title> <published>2024-11-07T12:30:00Z</published> <updated>2024-11-22T15:07:27Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/11/07/2976557/0/fr/Th%C3%A9rapeutique-Knight-d%C3%A9clare-ses-r%C3%A9sultats-du-troisi%C3%A8me-trimestre-de-2024.html" /> <category term="TSX:GUD" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA4990531069" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">MONTRÉAL, 07 nov. 2024 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight » ou la « Société »), société pharmaceutique spécialisée panaméricaine (à l’exclusion des É.-U.) de premier plan, a annoncé aujourd’hui ses résultats financiers pour le troisième trimestre clos le 30 septembre 2024. Tous les montants sont exprimés en milliers de dollars canadiens (sauf indication contraire), à l’exception du nombre d’actions et des montants par action.</p>]]></content> <dc:identifier>2976557</dc:identifier> <dc:language>fr</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Thérapeutique Knight inc.</dc:contributor> <dc:modified>Thu, 07 Nov 2024 12:30 GMT</dc:modified> <dc:subject>Calendar of Events</dc:subject> <dc:subject>Earnings Releases and Operating Results</dc:subject> <dc:subject>Conference Calls/ Webcasts</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/10/31/2972486/0/en/Notice-of-Knight-Therapeutics-Third-Quarter-2024-Results-Conference-Call.html</id> <title type="text">Notice of Knight Therapeutics' Third Quarter 2024 Results Conference Call</title> <published>2024-10-31T11:30:00Z</published> <updated>2024-11-22T15:07:27Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/10/31/2972486/0/en/Notice-of-Knight-Therapeutics-Third-Quarter-2024-Results-Conference-Call.html" /> <category term="TSX:GUD" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA4990531069" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">MONTREAL, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2024 financial results on Thursday, November 7, 2024, prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.</p>]]></content> <dc:identifier>2972486</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Knight Therapeutics</dc:contributor> <dc:modified>Thu, 31 Oct 2024 11:30 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> <dc:subject>Conference Calls/ Webcasts</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/10/31/2972486/0/fr/Avis-de-conf%C3%A9rence-t%C3%A9l%C3%A9phonique-de-Th%C3%A9rapeutique-Knight-sur-ses-r%C3%A9sultats-du-troisi%C3%A8me-trimestre-2024.html</id> <title type="text">Avis de conférence téléphonique de Thérapeutique Knight sur ses résultats du troisième trimestre 2024</title> <published>2024-10-31T11:30:00Z</published> <updated>2024-11-22T15:07:27Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/10/31/2972486/0/fr/Avis-de-conf%C3%A9rence-t%C3%A9l%C3%A9phonique-de-Th%C3%A9rapeutique-Knight-sur-ses-r%C3%A9sultats-du-troisi%C3%A8me-trimestre-2024.html" /> <category term="TSX:GUD" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA4990531069" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">MONTRÉAL, 31 oct. 2024 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight »), société pharmaceutique spécialisée panaméricaine (hors États-Unis) et chef de file, publiera ses résultats financiers du troisième trimestre 2024, ce jeudi 7 novembre 2024 avant l’ouverture du marché. À la suite de cette publication, Knight sera l’hôte d’une conférence téléphonique et d’une webémission. Knight invite cordialement toutes les parties intéressées à participer à cet appel.</p>]]></content> <dc:identifier>2972486</dc:identifier> <dc:language>fr</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Thérapeutique Knight inc.</dc:contributor> <dc:modified>Thu, 31 Oct 2024 11:30 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> <dc:subject>Conference Calls/ Webcasts</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/10/15/2963217/0/en/Knight-Therapeutics-Announces-Approval-of-Minjuvi-tafasitamab-in-Mexico.html</id> <title type="text">Knight Therapeutics Announces Approval of Minjuvi® (tafasitamab) in Mexico</title> <published>2024-10-15T12:30:00Z</published> <updated>2024-11-22T15:07:27Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/10/15/2963217/0/en/Knight-Therapeutics-Announces-Approval-of-Minjuvi-tafasitamab-in-Mexico.html" /> <category term="TSX:GUD" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA4990531069" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">MONTREAL, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V. has obtained regulatory approval by COFEPRIS, the Mexican health regulatory agency, for Minjuvi<sup>®</sup> (tafasitamab) in combination with lenalidomide followed by Minjuvi<sup>®</sup> monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), who are not eligible for autologous stem cell transplantation (ASCT).<br></p>]]></content> <dc:identifier>2963217</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Knight Therapeutics</dc:contributor> <dc:modified>Tue, 15 Oct 2024 12:31 GMT</dc:modified> <dc:subject>Health</dc:subject> <dc:subject>Product / Services Announcement</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/10/15/2963217/0/fr/Th%C3%A9rapeutique-Knight-annonce-l-approbation-de-Minjuvi-tafasitamab-au-Mexique.html</id> <title type="text">Thérapeutique Knight annonce l’approbation de Minjuvi® (tafasitamab) au Mexique</title> <published>2024-10-15T12:30:00Z</published> <updated>2024-11-22T15:07:27Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/10/15/2963217/0/fr/Th%C3%A9rapeutique-Knight-annonce-l-approbation-de-Minjuvi-tafasitamab-au-Mexique.html" /> <category term="TSX:GUD" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA4990531069" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">MONTRÉAL, 15 oct. 2024 (GLOBE NEWSWIRE) -- Thérapeutique Knight Inc. (TSX : GUD) (« Knight »), société pharmaceutique spécialisée panaméricaine (hors États-Unis), a annoncé aujourd’hui que sa filiale mexicaine, Grupo Biotoscana de Especialidad S.A. de C.V. a obtenu l’approbation règlementaire de COFEPRIS, agence mexicaine de réglementation de santé, pour Minjuvi<sup>®</sup> (tafasitamab) en association avec le lénalidomide suivi d’une monothérapie avec Minjuvi<sup>®</sup> pour le traitement de patients adultes atteints d’un lymphome diffus à grandes cellules B (DLBCL) récidivant ou réfractaire, non admissibles à une autogreffe de cellules souches (ASCT).<br></p>]]></content> <dc:identifier>2963217</dc:identifier> <dc:language>fr</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Thérapeutique Knight inc.</dc:contributor> <dc:modified>Tue, 15 Oct 2024 12:31 GMT</dc:modified> <dc:subject>Health</dc:subject> <dc:subject>Product / Services Announcement</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/09/27/2954576/0/en/Knight-Therapeutics-Inc-places-No-397-on-The-Globe-and-Mail-s-sixth-annual-ranking-of-Canada-s-Top-Growing-Companies.html</id> <title type="text">Knight Therapeutics Inc. places No. 397 on The Globe and Mail's sixth annual ranking of Canada's Top Growing Companies</title> <published>2024-09-27T14:22:35Z</published> <updated>2024-11-22T15:07:27Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/09/27/2954576/0/en/Knight-Therapeutics-Inc-places-No-397-on-The-Globe-and-Mail-s-sixth-annual-ranking-of-Canada-s-Top-Growing-Companies.html" /> <category term="TSX:GUD" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA4990531069" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">MONTREAL, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it has ranked No. 397 on the 2024 Report on Business magazine’s ranking of Canada’s Top Growing Companies.<br></p>]]></content> <dc:identifier>2954576</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Knight Therapeutics</dc:contributor> <dc:modified>Fri, 27 Sep 2024 14:22 GMT</dc:modified> <dc:subject>Contests/Awards</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/09/27/2954576/0/fr/Th%C3%A9rapeutique-Knight-inc-se-hisse-au-397e-rang-des-soci%C3%A9t%C3%A9s-canadiennes-%C3%A0-forte-croissance-dans-le-sixi%C3%A8me-classement-du-Globe-and-Mail.html</id> <title type="text">Thérapeutique Knight inc. se hisse au 397e rang des sociétés canadiennes à forte croissance dans le sixième classement du Globe and Mail</title> <published>2024-09-27T14:22:35Z</published> <updated>2024-11-22T15:07:27Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/09/27/2954576/0/fr/Th%C3%A9rapeutique-Knight-inc-se-hisse-au-397e-rang-des-soci%C3%A9t%C3%A9s-canadiennes-%C3%A0-forte-croissance-dans-le-sixi%C3%A8me-classement-du-Globe-and-Mail.html" /> <category term="TSX:GUD" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA4990531069" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">MONTRÉAL, 27 sept. 2024 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight » ou la « Société »), est heureuse d’annoncer son classement à la 397<sup>e</sup> place des entreprises à forte croissance au Canada publié pour 2024 par le magazine Report on Business.<br></p>]]></content> <dc:identifier>2954576</dc:identifier> <dc:language>fr</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Thérapeutique Knight inc.</dc:contributor> <dc:modified>Fri, 27 Sep 2024 14:22 GMT</dc:modified> <dc:subject>Contests/Awards</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/08/08/2926829/0/en/Knight-Therapeutics-Reports-Second-Quarter-2024.html</id> <title type="text">Knight Therapeutics Reports Second Quarter 2024</title> <published>2024-08-08T11:30:00Z</published> <updated>2024-11-22T15:07:27Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/08/08/2926829/0/en/Knight-Therapeutics-Reports-Second-Quarter-2024.html" /> <category term="TSX:GUD" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA4990531069" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[Achieved Record Revenues & Increased 2024 Revenue Guidance <pre>Achieved Record Revenues & Increased 2024 Revenue Guidance</pre>]]></content> <dc:identifier>2926829</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Knight Therapeutics</dc:contributor> <dc:modified>Thu, 08 Aug 2024 11:30 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> <dc:subject>Conference Calls/ Webcasts</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/08/08/2926829/0/fr/Th%C3%A9rapeutique-Knight-d%C3%A9clare-ses-r%C3%A9sultats-du-deuxi%C3%A8me-trimestre-de-2024.html</id> <title type="text">Thérapeutique Knight déclare ses résultats du deuxième trimestre de 2024</title> <published>2024-08-08T11:30:00Z</published> <updated>2024-11-22T15:07:27Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/08/08/2926829/0/fr/Th%C3%A9rapeutique-Knight-d%C3%A9clare-ses-r%C3%A9sultats-du-deuxi%C3%A8me-trimestre-de-2024.html" /> <category term="TSX:GUD" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA4990531069" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[Produits des activités ordinaires records et augmentation des prévisions pour les produits des activités ordinaires pour 2024 <pre>Produits des activités ordinaires records et augmentation des prévisions pour les produits des activités ordinaires pour 2024</pre>]]></content> <dc:identifier>2926829</dc:identifier> <dc:language>fr</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Thérapeutique Knight inc.</dc:contributor> <dc:modified>Thu, 08 Aug 2024 11:30 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> <dc:subject>Conference Calls/ Webcasts</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/08/01/2922670/0/en/Notice-of-Knight-Therapeutics-Second-Quarter-2024-Results-Conference-Call.html</id> <title type="text">Notice of Knight Therapeutics' Second Quarter 2024 Results Conference Call</title> <published>2024-08-01T11:30:00Z</published> <updated>2024-11-22T15:07:27Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/08/01/2922670/0/en/Notice-of-Knight-Therapeutics-Second-Quarter-2024-Results-Conference-Call.html" /> <category term="TSX:GUD" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA4990531069" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">MONTREAL, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2024 financial results on Thursday, August 8, 2024 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.<br></p>]]></content> <dc:identifier>2922670</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Knight Therapeutics</dc:contributor> <dc:modified>Thu, 01 Aug 2024 11:30 GMT</dc:modified> <dc:subject>Calendar of Events</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/08/01/2922670/0/fr/Avis-de-conf%C3%A9rence-t%C3%A9l%C3%A9phonique-de-Th%C3%A9rapeutique-Knight-sur-ses-r%C3%A9sultats-du-deuxi%C3%A8me-trimestre-2024.html</id> <title type="text">Avis de conférence téléphonique de Thérapeutique Knight sur ses résultats du deuxième trimestre 2024</title> <published>2024-08-01T11:30:00Z</published> <updated>2024-11-22T15:07:27Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/08/01/2922670/0/fr/Avis-de-conf%C3%A9rence-t%C3%A9l%C3%A9phonique-de-Th%C3%A9rapeutique-Knight-sur-ses-r%C3%A9sultats-du-deuxi%C3%A8me-trimestre-2024.html" /> <category term="TSX:GUD" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA4990531069" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">MONTRÉAL, 01 août 2024 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight »), société pharmaceutique spécialisée panaméricaine (hors États-Unis) et chef de file, publiera ses résultats financiers du deuxième trimestre 2024, ce jeudi 8 août 2024 avant l’ouverture du marché. À la suite de cette publication, Knight sera l’hôte d’une conférence téléphonique et d’une webémission. Knight invite cordialement toutes les parties intéressées à participer à cet appel.<br></p>]]></content> <dc:identifier>2922670</dc:identifier> <dc:language>fr</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Thérapeutique Knight inc.</dc:contributor> <dc:modified>Thu, 01 Aug 2024 11:30 GMT</dc:modified> <dc:subject>Calendar of Events</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/07/11/2911727/0/en/Knight-Announces-Normal-Course-Issuer-Bid.html</id> <title type="text">Knight Announces Normal Course Issuer Bid</title> <published>2024-07-11T11:30:00Z</published> <updated>2024-11-22T15:07:27Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/07/11/2911727/0/en/Knight-Announces-Normal-Course-Issuer-Bid.html" /> <category term="TSX:GUD" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA4990531069" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">MONTREAL, July 11, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("<strong>Knight</strong>" or the "<strong>Company </strong>"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today acceptance by the Toronto Stock Exchange (the "TSX") of the Company's Notice of Intention to Make a Normal Course Issuer Bid ("NCIB"). Pursuant to the NCIB, the Company proposes to purchase, from time to time over the next 12 months, if considered advisable, up to 5,312,846 common shares of the Company, being approximately 10% of its public float of 53,128,463 common shares, as of June 30, 2024. As of June 30, 2024, there were a total of 101,327,297 common shares issued and outstanding. Purchases may commence on July 15, 2024 and will conclude on the earlier of the date on which purchases under the bid have been completed and July 14, 2025. The Company may purchase up to a daily maximum of 16,855 common shares (being 25% of the average daily trading volume of 67,421 common shares, for the last six calendar months). The common shares may be purchased for cancellation through the facilities of the TSX or through alternative Canadian trading systems at times and in numbers to be determined by the Company. The Company had previously sought and obtained approval from the TSX to purchase up to 5,999,524 common shares under an NCIB and the Company has, in the twelve months preceding this announcement, purchased such 5,999,524 common shares through the facilities of the TSX and alternative Canadian trading systems at a weighted average price per share of $4.87.<br></p>]]></content> <dc:identifier>2911727</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Knight Therapeutics</dc:contributor> <dc:modified>Thu, 11 Jul 2024 11:30 GMT</dc:modified> <dc:subject>Changes in company's own shares</dc:subject> <dc:subject>Major shareholder announcements</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/07/11/2911727/0/fr/Knight-annonce-une-offre-publique-de-rachat-dans-le-cours-normal-des-activit%C3%A9s.html</id> <title type="text">Knight annonce une offre publique de rachat dans le cours normal des activités</title> <published>2024-07-11T11:30:00Z</published> <updated>2024-11-22T15:07:27Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/07/11/2911727/0/fr/Knight-annonce-une-offre-publique-de-rachat-dans-le-cours-normal-des-activit%C3%A9s.html" /> <category term="TSX:GUD" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA4990531069" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">MONTRÉAL, 11 juill. 2024 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« <strong>Knight</strong> » ou « <strong>la Société</strong> »), société pharmaceutique spécialisée panaméricaine (hors États-Unis) et chef de file, a annoncé aujourd’hui l’acceptation par la Bourse de Toronto (la « TSX ») de l’avis d’intention de la Société de présenter une offre publique de rachat dans le cours normal des activités (« OPRCNA »). Conformément à cette OPRCNA, la Société propose d’acheter, de temps en temps durant les 12 prochains mois, si elle le juge opportun, jusqu’à 5 312 846 actions ordinaires de la Société, ce qui représente environ 10 % de son flottant de 53 128 463 actions ordinaires, en date du 30 juin 2024. Au 30 juin 2024, un total de 101 327 297 actions ordinaires étaient émises et en circulation. Les achats pourront débuter le 15 juillet 2024 et se terminer à la première date entre la date de fin des achats dans le cadre de l’offre et le 14 juillet 2025. La Société peut acquérir jusqu’à un maximum quotidien de 16 855 actions ordinaires (représentant 25 % du volume quotidien moyen des transactions de 67 421 actions ordinaires, au cours des six derniers mois civils). Les actions ordinaires pourront être achetées pour annulation par le biais de la TSX ou d’autres systèmes de négociation canadiens, à des dates et en des quantités que la Société déterminera. La Société a précédemment sollicité et obtenu l’approbation de la TSX pour l’achat d’un maximum de 5 999 524 actions ordinaires dans le cadre d’une OPRCNA et la Société a, durant les douze mois précédant la présente annonce, acquis ces 5 999 524 actions ordinaires par le biais de la TSX et d’autres systèmes de négociation canadiens à un coût moyen pondéré unitaire de 4,87 $.<br></p>]]></content> <dc:identifier>2911727</dc:identifier> <dc:language>fr</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Thérapeutique Knight inc.</dc:contributor> <dc:modified>Thu, 11 Jul 2024 11:30 GMT</dc:modified> <dc:subject>Changes in company's own shares</dc:subject> <dc:subject>Major shareholder announcements</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/05/09/2878648/0/en/Knight-Therapeutics-Reports-First-Quarter-2024-Results.html</id> <title type="text">Knight Therapeutics Reports First Quarter 2024 Results</title> <published>2024-05-09T11:30:00Z</published> <updated>2024-11-22T15:07:27Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/05/09/2878648/0/en/Knight-Therapeutics-Reports-First-Quarter-2024-Results.html" /> <category term="TSX:GUD" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA4990531069" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2024. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified.<br></p>]]></content> <dc:identifier>2878648</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Knight Therapeutics</dc:contributor> <dc:modified>Thu, 09 May 2024 11:30 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/05/09/2878648/0/fr/Th%C3%A9rapeutique-Knight-d%C3%A9clare-ses-r%C3%A9sultats-du-premier-trimestre-de-2024.html</id> <title type="text">Thérapeutique Knight déclare ses résultats du premier trimestre de 2024</title> <published>2024-05-09T11:30:00Z</published> <updated>2024-11-22T15:07:27Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/05/09/2878648/0/fr/Th%C3%A9rapeutique-Knight-d%C3%A9clare-ses-r%C3%A9sultats-du-premier-trimestre-de-2024.html" /> <category term="TSX:GUD" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA4990531069" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="left">MONTRÉAL, 09 mai 2024 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight » ou la « Société »), une société pharmaceutique spécialisée panaméricaine (à l’exclusion des É.-U.) de premier plan, a annoncé aujourd’hui ses résultats financiers pour le premier trimestre clos le 31 mars 2024. Tous les montants sont exprimés en milliers de dollars canadiens (sauf indication contraire), à l’exception du nombre d’actions et des montants par action.<br></p>]]></content> <dc:identifier>2878648</dc:identifier> <dc:language>fr</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Thérapeutique Knight inc.</dc:contributor> <dc:modified>Thu, 09 May 2024 11:30 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/05/09/2878656/0/en/Knight-Therapeutics-Enters-into-Exclusive-Supply-and-Distribution-Agreement-with-Ironshore-Pharmaceuticals-Development-Inc-for-JORNAY-PM-for-Canada-and-Latin-America.html</id> <title type="text">Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM® for Canada and Latin America</title> <published>2024-05-09T11:30:00Z</published> <updated>2024-11-22T15:07:27Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/05/09/2878656/0/en/Knight-Therapeutics-Enters-into-Exclusive-Supply-and-Distribution-Agreement-with-Ironshore-Pharmaceuticals-Development-Inc-for-JORNAY-PM-for-Canada-and-Latin-America.html" /> <category term="TSX:GUD" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA4990531069" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an exclusive supply and distribution agreement with Ironshore Pharmaceuticals & Development, Inc., a wholly owned subsidiary of Ironshore Therapeutics, Inc. (“Ironshore”), granting Knight the rights to seek regulatory approval and commercialize <strong>JORNAY PM</strong><sup><strong>®</strong></sup> in Canada and Latin America. Currently approved in the US, <strong>JORNAY PM</strong><sup><strong>®</strong></sup>, is an extended-release formulation of methylphenidate, a stimulant medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD). Financial terms of the agreement were not disclosed.<br></p>]]></content> <dc:identifier>2878656</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Knight Therapeutics</dc:contributor> <dc:modified>Thu, 09 May 2024 11:30 GMT</dc:modified> <dc:subject>Business Contracts</dc:subject> <dc:subject>Health</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/05/09/2878656/0/fr/Th%C3%A9rapeutique-Knight-conclut-une-entente-exclusive-d-approvisionnement-et-de-distribution-avec-Ironshore-Pharmaceuticals-Development-Inc-pour-JORNAY-PM-pour-le-Canada-et-l-Am%C3%A9rique.html</id> <title type="text">Thérapeutique Knight conclut une entente exclusive d’approvisionnement et de distribution avec Ironshore Pharmaceuticals & Development, Inc. pour JORNAY PM® pour le Canada et l’Amérique latine</title> <published>2024-05-09T11:30:00Z</published> <updated>2024-11-22T15:07:27Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/05/09/2878656/0/fr/Th%C3%A9rapeutique-Knight-conclut-une-entente-exclusive-d-approvisionnement-et-de-distribution-avec-Ironshore-Pharmaceuticals-Development-Inc-pour-JORNAY-PM-pour-le-Canada-et-l-Am%C3%A9rique.html" /> <category term="TSX:GUD" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA4990531069" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">MONTRÉAL, 09 mai 2024 (GLOBE NEWSWIRE) -- Thérapeutique Knight Inc. (TSX : GUD) (« Knight »), société pharmaceutique spécialisée panaméricaine (hors États-Unis), a annoncé aujourd’hui la conclusion d’une entente exclusive d’approvisionnement et de distribution avec Ironshore Pharmaceuticals & Development, Inc., une filiale en propriété exclusive d’Ironshore Therapeutics, Inc. (« Ironshore »), octroyant à Knight les droits de solliciter l’approbation réglementaire et de commercialiser <strong>JORNAY PM</strong><sup><strong>®</strong></sup> au Canada et en Amérique latine. Présentement approuvé aux États-Unis, <strong>JORNAY PM</strong><sup><strong>®</strong></sup> est une formulation à libération prolongée de méthylphénidate, médicament stimulant destiné au traitement du trouble du déficit d’attention avec hyperactivité (TDAH). Les conditions financières de l’entente n’ont pas été divulguées.<br></p>]]></content> <dc:identifier>2878656</dc:identifier> <dc:language>fr</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Thérapeutique Knight inc.</dc:contributor> <dc:modified>Thu, 09 May 2024 11:30 GMT</dc:modified> <dc:subject>Business Contracts</dc:subject> <dc:subject>Health</dc:subject> </entry> </feed>